Forte Biosciences, Inc.

FBRX
$36.70 (+ $16.12 + 78.33%)
Last updated: 2026-07-10 05:26 UTC
FBRX Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS34962G1094
CUSIP34962G109
Market Price36.7
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-0.08
Market Cap$343.7M
Book Value4.72
Price to Book5.817
Beta3.25
52w High31.27
52w Low4.9
Next Earnings DateN/A

Forte Biosciences, Inc. trades under ticker FBRX on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US34962G1094, CUSIP 34962G109.

About the Company
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Price History